Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-03-10 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 1% confidence The document is titled "Genmab Announces Johnson & Johnson Decision Regarding HexaBody®- CD38" and is explicitly labeled as a "Company Announcement." It details a specific corporate event: J&J's decision not to exercise an option and Genmab's subsequent decision regarding a drug candidate. It also mentions a conference call to discuss the event. This type of announcement, which communicates a significant business development (licensing/pipeline update) but is not a full financial report (like 10-K or IR) or a formal regulatory filing like a proxy statement, fits best under the general category of corporate news or regulatory updates. Since it is a specific, material business update that doesn't fit the other specialized codes (like DIV, CAP, MANG), the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially a specific type of corporate action announcement. Given the context of a major partnership decision and pipeline update, RNS serves as the best fit for a material, non-standardized announcement.
2025-03-10 English
Regulatory Filings 2025
Regulatory Filings Classification · 1% confidence The document is titled "Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38" and is explicitly labeled as a "Company Announcement." It details a specific corporate event (a licensing option decision) and includes forward-looking statements, contact information, and a reference to a specific Company Announcement number (09). Crucially, it concludes with an "Attachment" link to a file named "10032025_CA09_JNJ Decision GEN3014". This structure—a brief announcement summarizing a material event and pointing to an attachment—is characteristic of a general regulatory filing or news release that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it is a formal, non-standardized announcement of corporate news, the most appropriate fallback category is Regulatory Filings (RNS). It is not a full report (10-K, IR), an earnings release (ER), or a presentation (IP).
2025-03-10 English
6-K
Foreign Filer Report
2025-03-06 English
6-K
Foreign Filer Report
2025-03-04 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons' and explicitly states it discloses transactions made by managerial employees in accordance with Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This type of filing specifically reports personal share transactions by company directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS). Although it is a company announcement, the content is highly specific to insider trading reports, making DIRS a more precise classification than the general RPA or RNS.
2025-03-04 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document explicitly states it is a 'Company Announcement' and references 'Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523'. This regulation mandates the disclosure of transactions made by managerial employees and closely associated persons (insider trading/directors' dealings). The content details specific transactions (Acquisition due to vesting of restricted stock units) by named executives (Jan van de Winkel, Anthony Pagano, Martin Schultz). This perfectly matches the definition of Director's Dealing (DIRS). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns specific insider transactions.
2025-03-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.